Percutaneous Coronary Atherectomy with Intraluminal Device with MCC DRG Reimbursement

DRG 359 encompasses percutaneous coronary atherectomy with intraluminal device placement in patients with a Major Complication or Comorbidity and involves complex percutaneous coronary interventions that increase resource needs. Proper assignment of this Diagnosis-Related Group impacts inpatient reimbursement from Medicare because the Major Complication or Comorbidity status elevates payment relative to lower-severity groups.

DRG 359 Overview

DRG 359 covers hospital admissions for percutaneous coronary atherectomy with placement of an intraluminal device in patients who have a Major Complication or Comorbidity. These are high-acuity percutaneous coronary interventions performed for complex coronary lesions that often require specialized equipment and longer procedure times. This Diagnosis-Related Group matters for Medicare payment because cases with a Major Complication or Comorbidity typically generate higher resource use and result in higher inpatient reimbursement relative to lower-severity groupings. Accurate clinical documentation of the Major Complication or Comorbidity drives appropriate Diagnosis-Related Group assignment and payment.

Trials comparing different intraluminal device strategies or adjunctive technologies used during percutaneous coronary atherectomy procedures in patients with complex coronary lesions (for example heavily calcified or in-stent restenosis): these studies enroll adults undergoing percutaneous coronary atherectomy with a focus on procedural endpoints such as procedural success, device deliverability, acute lumen gain, and peri-procedural complications. They are relevant because device choice and technique directly affect index hospitalization resource use, complication rates, and short-term readmissions that drive DRG costs and provider quality metrics.
Comparative effectiveness studies of atherectomy-based revascularization versus alternative percutaneous strategies (such as high-pressure ballooning, specialty balloons, or rotational/laser atherectomy without intraluminal adjuncts) in high-risk cohorts including elderly patients, those with multivessel disease, or prior coronary stents: these studies evaluate medium-term outcomes like target lesion revascularization, myocardial infarction, and major adverse cardiovascular events over months to a year. Payers and hospitals benefit from evidence on relative durability and downstream utilization because it informs expected longer-term costs, need for repeat procedures, and case mix considerations for DRG budgeting.
Post-discharge outcomes and health services research examining readmission drivers, functional status, quality of life, and cost-effectiveness after percutaneous coronary atherectomy with intraluminal devices in patients with significant comorbidities (such as chronic kidney disease, diabetes, or heart failure): these observational cohorts or pragmatic trials assess patient-centered outcomes, adherence to guideline-directed medical therapy, and patterns of post-acute care. This area is important to providers and payers to identify interventions that reduce avoidable readmissions, optimize discharge dispositions, and improve overall value of care for patients classified under this DRG.

Trials comparing different intraluminal device strategies or adjunctive technologies used during percutaneous coronary atherectomy procedures in patients with complex coronary lesions (for example heavily calcified or in-stent restenosis): these studies enroll adults undergoing percutaneous coronary atherectomy with a focus on procedural endpoints such as procedural success, device deliverability, acute lumen gain, and peri-procedural complications. They are relevant because device choice and technique directly affect index hospitalization resource use, complication rates, and short-term readmissions that drive DRG costs and provider quality metrics.
Comparative effectiveness studies of atherectomy-based revascularization versus alternative percutaneous strategies (such as high-pressure ballooning, specialty balloons, or rotational/laser atherectomy without intraluminal adjuncts) in high-risk cohorts including elderly patients, those with multivessel disease, or prior coronary stents: these studies evaluate medium-term outcomes like target lesion revascularization, myocardial infarction, and major adverse cardiovascular events over months to a year. Payers and hospitals benefit from evidence on relative durability and downstream utilization because it informs expected longer-term costs, need for repeat procedures, and case mix considerations for DRG budgeting.
Post-discharge outcomes and health services research examining readmission drivers, functional status, quality of life, and cost-effectiveness after percutaneous coronary atherectomy with intraluminal devices in patients with significant comorbidities (such as chronic kidney disease, diabetes, or heart failure): these observational cohorts or pragmatic trials assess patient-centered outcomes, adherence to guideline-directed medical therapy, and patterns of post-acute care. This area is important to providers and payers to identify interventions that reduce avoidable readmissions, optimize discharge dispositions, and improve overall value of care for patients classified under this DRG.

OpenPayer

Summary & Overview

Percutaneous Coronary Atherectomy with Intraluminal Device with MCC: Inpatient Reimbursement Overview

DRG 359 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes